Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model
Authors:
- 30 August 2012
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 18 (17) , 4621-4632
Abstract
Purpose: Aurora kinases play a crucial role in cell-cycle control. Uncontrolled expression of aurora kinases causes aneuploidy and tumor growth. As conservative treatment options for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) are disappointing, aurora kinases may be an interesting target for novel therapeutic strategies. Experimental Design: Human GEP-NETs were tested for aurora kinase expression. The efficacy of the new aurora kinase inhibitor danusertib was evaluated in two human GEP-NET cell lines (BON1 and QGP) in vitro and in vivo. Results: The majority of ten insulinomas and all 33 nonfunctional pancreatic or midgut GEP-NETs expressed aurora A despite a mostly high degree of cell differentiation. Both human GEP-NET cell lines expressed aurora kinase A and B, and high Ser10 phosphorylation of histone H3 revealed increased aurora B activity. Remarkably, danusertib led to cell-cycle arrest and completely inhibited cell proliferation of the GEP-NET cells in vitro. Decreased phosphorylation of histone H3 indicated effective aurora B inhibition. In a subcutaneous murine xenograft model, danusertib significantly reduced tumor growth in vivo compared with controls or mice treated with streptozotocine/5-fluorouracil. As a consequence, decreased levels of tumor marker chromogranin A were found in mouse serum samples. In a newly developed orthotopic model for GEP-NET liver metastases by intrasplenic tumor cell transplantation, dynamic MRI proved significant growth inhibition of BON1- and QGP-derived liver metastases. Conclusions: These results show that danusertib may impose a new therapeutic strategy for aurora kinase expressing metastasized GEP-NETs. Clin Cancer Res; 18(17); 4621–32. ©2012 AACR.Keywords
This publication has 40 references indexed in Scilit:
- Somatostatin Receptor-Targeted Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine TumorsEndocrinology and Metabolism Clinics of North America, 2011
- Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomasCancer Treatment Reviews, 2010
- Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertibInvestigational New Drugs, 2010
- Loss of Nuclear p27 Expression and Its Prognostic Role in Relation to Cyclin E and p53 Mutation in Gastroenteropancreatic Neuroendocrine TumorsClinical Cancer Research, 2008
- P38 MAP Kinase Signaling Is Required for the Conversion of CD4+CD25− T Cells into iTregPLOS ONE, 2008
- Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer GrowthClinical Cancer Research, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- Hepatocyte Transplantation Activates Hepatic Stellate Cells With Beneficial Modulation of Cell Engraftment in the Rat *Hepatology, 2005
- Hepatic Targeting of Transplanted Liver Sinusoidal Endothelial Cells in Intact Mice *Hepatology, 2005
- Ablative Therapies for Liver Metastases of Gastroenteropancreatic Endocrine TumorsNeuroendocrinology, 2004